BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and immuno-modulatory antibodies for cancer therapy. Its technology platforms include F.I.R.S.T. and n-CoDeR. The company was founded in 1996 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company